AstraZeneca cancer drug hits second goal by extending survival
May 25, 2018 at 03:27 AM EDT
LONDON, May 25 (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.
